Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Chugai Aims at Top Share with Actemra
July 14, 2008
- Council Recommends Introduction of Reference Price System
July 14, 2008
- Shionogi, DSP Start Marketing Irbesartan
July 14, 2008
- SCJ Calls For Revision of Medical Expenditure Curtailment Policy
July 14, 2008
- Ferring to Start Independent Business by Copromoting Desmopressin with Kyowa Hakko
July 14, 2008
- REGULATORY NEWS IN BRIEF
July 14, 2008
- INTERPHEX JAPAN 2008
July 14, 2008
- MEDICAL DEVICE NEWS IN BRIEF
July 14, 2008
- Traditional Business Model Seeing the End Coming: Mr Makov
July 14, 2008
- OPINION
July 14, 2008
- Nihon Chouzai Settles Prices with All Wholesalers by End of June
July 14, 2008
- Treatment with Erbitux Requires KRAS Gene Testing to Predict Efficacy
July 14, 2008
- BUSINESS NEWS IN BRIEF
July 14, 2008
- Biologics Provide a New Approach to RA Treatment in Japan
July 14, 2008
- Avapro Leaps to Top Position in May: Rep Track Survey
July 14, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 14, 2008
- 70 Amlodipine Generics Listed from 34 Companies
July 14, 2008
- Initial Goals in Action Program for Generics Almost Met
July 14, 2008
- Pharmacists Explain Generics to Only 11% of Patients: Survey
July 14, 2008
- GENERICS NEWS IN BRIEF
July 14, 2008
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…